Literature DB >> 18490383

Tumor stroma marker endosialin (Tem1) is a binding partner of metastasis-related protein Mac-2 BP/90K.

Renate Becker1, Martin C Lenter, Tobias Vollkommer, Anja M Boos, Dennis Pfaff, Hellmut G Augustin, Sven Christian.   

Abstract

Tumor development involves complex bidirectional interactions between tumor cells and host stromal cells. Endosialin (Tem1) has been identified as a highly O-glycosylated transmembrane glycoprotein, which is specifically expressed by tumor vessel-associated pericytes and stromal fibroblasts of a wide range of human tumors. Recent experiments in endosialin-deficient mice have unraveled a critical role of endosialin in site-specific tumor progression and metastasis. To molecularly understand the mechanisms of endosialin function, we aimed to identify extracellular endosialin ligands and identified Mac-2 BP/90K as a specific interaction partner. Detailed biochemical analyses identified a C-terminal fragment of Mac-2 BP/90K, which was shown to contain binding sites for galectin-3, and collagens as the structures responsible for endosialin binding. Subsequent expression analysis of Mac-2 BP/90K in vivo revealed weak or no expression in most normal tissues and strong up-regulation in tumor cells of human neoplastic tissues. Intriguingly, the expression patterns of Mac-2 BP/90K and endosialin were mutually exclusive in all human tissues. Correspondingly, loss-of-function adhesion experiments of Mac-2 BP/90K-expressing tumor cells on endosialin-expressing fibroblasts revealed a repulsive outcome of the Mac-2 BP/90K interaction. Taken together, the experiments identify a novel repulsive interaction between endosialin on stromal fibroblasts and Mac-2 BP/90K on tumor cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18490383     DOI: 10.1096/fj.07-101386

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  25 in total

Review 1.  The connectivity of lymphogenous and hematogenous tumor cell dissemination: biological insights and clinical implications.

Authors:  Jonathan P Sleeman; Blake Cady; Klaus Pantel
Journal:  Clin Exp Metastasis       Date:  2012-06-06       Impact factor: 5.150

2.  Shoc2-tranduced ERK1/2 motility signals--Novel insights from functional genomics.

Authors:  Myoungkun Jeoung; Eun Ryoung Jang; Jinpeng Liu; Chi Wang; Eric C Rouchka; Xiaohong Li; Emilia Galperin
Journal:  Cell Signal       Date:  2016-02-11       Impact factor: 4.315

Review 3.  C-type lectin family XIV members and angiogenesis.

Authors:  Supriya Borah; Dileep Vasudevan; Rajeeb K Swain
Journal:  Oncol Lett       Date:  2019-08-16       Impact factor: 2.967

4.  Rapid isolation of high-affinity human antibodies against the tumor vascular marker Endosialin/TEM1, using a paired yeast-display/secretory scFv library platform.

Authors:  Aizhi Zhao; Selene Nunez-Cruz; Chunsheng Li; George Coukos; Don L Siegel; Nathalie Scholler
Journal:  J Immunol Methods       Date:  2010-09-15       Impact factor: 2.303

5.  Identification of cellular targets in human intrahepatic cholangiocarcinoma using laser microdissection and accurate mass and time tag proteomics.

Authors:  Alexandre Dos Santos; Magali Court; Valérie Thiers; Sokhavuth Sar; Catherine Guettier; Didier Samuel; Christian Bréchot; Jérôme Garin; France Demaugre; Christophe D Masselon
Journal:  Mol Cell Proteomics       Date:  2010-05-31       Impact factor: 5.911

6.  Caveolin-1-/- null mammary stromal fibroblasts share characteristics with human breast cancer-associated fibroblasts.

Authors:  Federica Sotgia; Francesco Del Galdo; Mathew C Casimiro; Gloria Bonuccelli; Isabelle Mercier; Diana Whitaker-Menezes; Kristin M Daumer; Jie Zhou; Chenguang Wang; Sanjay Katiyar; Huan Xu; Emily Bosco; Andrew A Quong; Bruce Aronow; Agnieszka K Witkiewicz; Carlo Minetti; Philippe G Frank; Sergio A Jimenez; Erik S Knudsen; Richard G Pestell; Michael P Lisanti
Journal:  Am J Pathol       Date:  2009-03       Impact factor: 4.307

7.  Development of 124I immuno-PET targeting tumor vascular TEM1/endosialin.

Authors:  Ann-Marie Chacko; Chunsheng Li; Madhura Nayak; John L Mikitsh; Jia Hu; Catherine Hou; Luigi Grasso; Nicholas C Nicolaides; Vladimir R Muzykantov; Chaitanya R Divgi; George Coukos
Journal:  J Nucl Med       Date:  2014-02-13       Impact factor: 10.057

8.  Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model.

Authors:  Chunsheng Li; Ann-Marie Chacko; Jia Hu; Kosei Hasegawa; Jennifer Swails; Luigi Grasso; Wafik S El-Deiry; Nicholas Nicolaides; Vladimir R Muzykantov; Chaitanya R Divgi; George Coukos
Journal:  Cancer Biol Ther       Date:  2014-02-19       Impact factor: 4.742

9.  Dendritic cell-based immunotherapy for colon cancer using an HLA-A*0201-restricted cytotoxic T-lymphocyte epitope from tumor-associated antigen 90K.

Authors:  Ji Hee Lee; Myong-Suk Park; Jun-Eul Hwang; Sang-Hee Cho; Woo-Kyun Bae; Hyun-Jeong Shim; Dae-Eun Kim; Ik-Joo Chung
Journal:  Cell Mol Immunol       Date:  2013-03-25       Impact factor: 11.530

10.  Characterization of TEM1/endosialin in human and murine brain tumors.

Authors:  Eleanor B Carson-Walter; Bethany N Winans; Melissa C Whiteman; Yang Liu; Sally Jarvela; Hannu Haapasalo; Betty M Tyler; David L Huso; Mahlon D Johnson; Kevin A Walter
Journal:  BMC Cancer       Date:  2009-11-30       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.